The epstein-barr virus immediate-early gene product, BRLF1, interacts with the retinoblastoma protein during the viral lytic cycle

Journal of Virology

Volumn 72, Issue 10, 1998, Pages 8043-8051

  Zacny, Valerie L ^a   Wilson, Julie ^a   Pagano, Joseph S ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; ONCOPROTEIN; RETINOBLASTOMA PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CELL CYCLE; CELL PROLIFERATION; DNA BINDING; DNA SYNTHESIS; EPSTEIN BARR VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; RETINOBLASTOMA; VIRUS REPLICATION;

EID: 0031714557     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.10.8043-8051.1998     Document Type: Article

References (84)

1. Adams, P. D., and W. G. Kaelin. 1995. Transcriptional control by E2F. Semin. Cancer Biol. 6:99-108.
2. Almasan, A., Y. Yin, R. E. Kelly, E. Y. Lee, A. Bradley, W. Li, J. R. Bertino, and G. M. Wahl. 1995. Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. Proc. Natl. Acad. Sci. USA 92:5436-5440.
3. Arvanitakis, L., N. Yaseen, and S. Sharma. 1995. Latent membrane protein-1 induces cyclin D2 expression, pRb hyperphosphorylation, and loss of TGF-B1-mediated growth inhibition in EBV-positive B cells. J. lmmunol. 155:1047-1055.
4. Ben-Bassat, H., N. Goldblum, S. Mitrani, T. Goldblum, J. M. Yoffey, M. M. Cohen, Z. Bentwich, B. Ramot, E. Klein, and G. Klein. 1977. Establishment in continuous culture of a new type of lymphocyte from a 'Burkitt like' malignant lymphoma (line DG-75). Int. J. Cancer 19:27-33.
5. Biggen, M., M. Bodescot, M. Perricaudet, and P. Farrell. 1987. Epstein-Barr virus gene expression in P3HR1-superinfected Raji cells. J. Virol. 61:3120-3122.
6. Buisson, M., E. Manet, M.-C. Trescol-Biemont, H. Gruffat, B. Durand, and A. Sergeant. 1989. The Epstein-Barr virus (EBV) early protein EB2 is a posttranscriptional activator expressed under the control of EBV transcription factors EB1 and R. J. Virol. 63:5276-5284.
7. Cannell, E. J., P. J. Farrell, and A. J. Sinclair. 1996. Epstein-Barr virus exploits the normal cell pathway to regulate Rb activity during the immortalisation of primary B-cells. Oncogene 13:413-421.
8. 1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors. EMBO J. 15:2748-2759.
9. Chen, L. I., T. Nishinaka, K. Kwan, I. Kitabayashi, K. Yokoyama, Y.-H. F. Fu, S. Grunwald, and R. Chiu. 1994. The retinoblastoma gene product RB stimulates Sp1-mediated transcription by liberating Sp1 from a negative regulator. Mol. Cell. Biol. 14:4380-4389.
10. Chen, P.-L., D. J. Riley, S. Chen-Kiang, and W.-H. Lee. 1996. Retinoblastoma protein directly interacts with and activates the transcription factor NF-IL6. Proc. Natl. Acad. Sci. USA 93:465-469.
11. Chevallier-Greco, A., H. Gruffat, E. Manet, A. Calender, and A. Sergeant. 1989. The Epstein-Barr virus (EBV) DR enhancer contains two functionally different domains: domain A is constitutive, and cell specific, domain B is transactivated by the EBV early protein, R. J. Virol. 63:615-623.
12. Chevallier-Greco, A., E. Manet, P. Chavrier, C. Mosnier, J. Daillie, and A. Sergeant. 1986. Both Epstein-Barr virus (EBV) transactivators, EB1 and EB2, are required to activate transcription from an early promoter. EMBO J. 5:3243-3249.
13. Countryman, J., H. Jensen, R. Seibel, H. Wolf, and G. Miller. 1987. Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J. Virol. 61:2521-2528.
14. Countryman, J., and G. Miller. 1985. Activation of expression of latent Epstein-Barr herpes virus after gene transfer with a small clones subfragment of heterogeneous viral DNA. Proc. Natl. Acad. Sci. USA 82:4085-1089.
15. Cox, M., J. Leahy, and J. M. Hardwick. 1990. An enhancer within the divergent promoter of Epstein-Barr virus responds synergistically to the R and Z transactivators. J. Virol. 64:313-321.
16. Datta, A. K., R. J. Feighny, and J. S. Pagano. 1980. Induction of Epstein-Barr virus-associated DNA polymerase by 12-O-tetradecanoyl-phorbol-13-acetate. J. Biol. Chem. 255:5120-5125.
17. DeCaprio, J. A., J. W. Ludlow, J. Figge, J.-Y. Shew, C.-M. Huang, W.-H. Lee, E. Marsillo, E. Paucha, and D. M. Livingston. 1988. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 54:275-283.
18. Durfee, T., M. A. Mancini, D. Jones, S. J. Elledge, and W.-H. Lee. 1994. The amino-terminal region of the retinoblastoma gene product binds a novel nuclear matrix protein that co-localizes to centers for RNA processing. J. Cell Biol. 127:609-622.
19. Dyson, N., P. M. Howley, L. Munger, and E. Harlow. 1989. The human papillomavirus-16E7 oncoprotein is able to bind the retinoblastoma gene product. Science 243:943-947.
20. Farrell, P. J., D. T. Rowe, C. M. Rooney, and T. Kouzarides. 1989. EpsteinBarr virus BZLF1 transactivator specifically binds to a consensus sequence AP-1 site and is related to c-fos. EMBO J. 8:127-133.
21. Flemington, E., and S. H. Speck. 1990. Epstein-Barr virus BZLF1 transactivator induces the promoter of a cellular cognate gene, c-fos. J. Virol. 64: 4549-4552.
22. Flemington, E. K., A. E. Goldfield, and S. H. Speck. 1991. Efficient transcription of the Epstein-Barr virus immediate-early BZLF1 and BRLF1 genes requires protein synthesis. J. Virol. 65:7073-7077.
23. Furukawa, T., S. Tanaka, and S. A. Plotkin. 1975. Stimulation of macromolecular synthesis in guinea pig cells by human CMV. Proc. Soc. Exp. Biol. Med. 148:211-214.
24. Giot, J.-F., I. Mikaelian, M. Buisson, E. Manet, I. Joab, J.-C. Nicholas, and A. Sergeant. 1991. Transcriptional interference between the EBV transcription factors EB1 and R: both DNA-binding and activation domains of EB1 are required. Nucleic Acids Res. 19:1251-1258.
25. Grogan, E. J., J. Jenson, J. Countryman, L. Heston, L. Gradoville, and G. Miller. 1987. Transfection of a rearranged viral DNA fragment WZhet, stably converts latent Epstein-Barr virus infection to productive infection in lymphoid cells. Proc. Natl. Acad. Sci. USA 84:1332-1336.
26. Gutsch, D. E., D. B. Marcu, and S. C. Kenney. 1994. The Epstein-Barr virus BRLF1 gene product transactivates the murine and human c-myc promoters. Cell. Mol. Biol. 40:747-760.
27. Hagemeier, C., R. Caswell, G. Hayhurst, J. H. Sinclair, and T. Kouzarides. 1994. Functional interaction between the HCMV IE2 transactivator and the retinoblastoma protein. EMBO J. 13:2897-2903.
28. Hardwick, J. M., P. M. Lieberman, and S. D. Hayward. 1988. A new Epstein-Barr virus transactivator, R. induces expression of a cytoplasmic early antigen. J. Virol. 62:2274-2284.
29. Hardwick, J. M., L. Tse, N. Applegren, J. Nicholas, and V. M. A. 1992. The Epstein-Barr virus R transactivator (Rta) contains a complex, potent activation domain with properties different from those of VP16. J. Virol. 66:5500-5508.
30. Hilton, M. J., D. Mounghane, T. McLean, N. V. Contractor, J. O'Neil, K. Carpenter, and S. L. Bachenheimer. 1995. Induction by herpes simplex virus of free and heteromeric forms of E2F transcription factor. Virology 213:624-638.
31. Holley-Guthrie, E. A., E. B. Quinlivan, E.-C. Mar, and K. S. 1990. The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen D (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner. J. Virol. 64:3753-3759.
32. Horowitz, J. Personal communication.
33. Hu, Q. J., N. Dyson, and E. Harlow. 1990. The regions of the retinoblastoma protein needed for binding to adenovirus E1A or SV40 large T antigen are common sites for mutations. EMBO J. 9:1147-1155.
34. Huang, S., N. P. Wang, B. Y. Tseng, L. W.-H., and E. Y.-H. P. Lee. 1990. Two distinct and frequently mutated regions of retinoblastoma protein are required for binding to SV40 T antigen. EMBO J. 9:1815-1822.
35. Inman, G. J., and P. J. Farrell. 1995. Epstein-Barr virus EBNA-LP and transcription regulation properties of pRB, p107 and p53 in transfection assays. J. Gen. Virol. 79:2141-2149.
36. Kaelin, W. G., M. E. Ewen, and D. M. Livingston. 1990. Definition of the minimal simian virus 40 large T antigen-and adenovirus E1A-binding domain in the retinoblastoma gene product. Mol. Cell. Biol. 10:3761-3769.
37. Kenney, S., E. Holley-Guthrie, E.-C. Mar, and M. Smith. 1989. The Epstein-Barr virus BMLF1 promoter contains an enhancer element that is responsive to the BZLF1 and BRLF1 transactivators. J. Virol. 63:3878-3883.
38. Kieff, E. 1993. Epstein-Barr virus and its replication, p. 1889-1920. In B. N. Fields, D. M. Knipe, R. M. Chanock, M. S. Hirsch, J. L. Melnick, T. P. Monath, and B. Roizman (ed.), Fields virology, 2nd ed. Raven Press, New York, N.Y.
39. Kim, S. J., U. S. Onwuta, Y. I. Lee, R. Li, M. R. Botchan, and P. D. Robbins. 1992. The retinoblastoma gene product regulates Sp1-mediated transcription. Mol. Cell. Biol. 12:2455-2463.
40. Lam, E. W. F., and N. B. La Thangue. 1994. DP and E2F proteins: coordinating transcription with cell cycle progression. Curr. Opin. Cell Biol. 6:859-866.
41. Liebowitz, D., and E. Kieff. 1993. Epstein-Barr virus, p. 107-172. In B. Roizman, R. J. Whitely, and C. Lopez (ed.), The human herpesviruses. Raven Press, New York, N.Y.
42. Liu, C., N. D. Sista, and J. S. Pagano. 1996. Activation of the Epstein-Barr virus DNA polymerase promoter by the BRLF1 immediate-early protein is mediated through USF and E2F. J. Virol. 70:2545-2555.
43. Ludlow, J. W. 1993. Interactions between SV40 large-tumor antigen and the growth supressor proteins pRB and p53. FASEB J. 7:866-871.
44. Manet, E., A. Rigolet, H. Gruffat, J.-F. Giot, and A. Sergeant. 1991. Domains of the Epstein-Barr virus (EBV) transcription factor R required for dimerization, DNA binding and activation. Nucleic Acids Res. 19:2661-2667.
45. Mietz, J. A., T. Unger, J. M. Huibregtse, and P. M. Howley. 1992. The transcriptional transactivation function of wild type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J. 11:5013-5020.
46. Moran, E. 1993. Interaction of adenoviral proteins with pRb and p53. FASEB J. 7:880-885.
47. Nevins, J. R. 1992. A link between the Rb tumor suppressor protein and viral oncoproteins. Science 258:424-429.
48. Pagano, J. S. 1991. Epstein-Barr virus, p. 1499-1503. In N. Kelley (ed.), Textbook of internal medicine, 2nd ed. Lippincott, Philadelphia, Pa.
49. Parker, G. A., T. Crook, M. Bain, E. A. Sara, P. J. Farrell, and M. J. Allday. 1996. Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Oncogene 13:2541-2549.
50. Qian, Y., C. Luckey, L. Horton, M. Esser, and D. J. Templeton. 1992. Biological function of the retinoblastoma protein requires distinct domains for hyperphosphorylation and transcription factor binding. Mol. Cell. Biol. 12:5363-5372.
51. Quinlivan, E. B. Unpublished data.
52. Quinlivan, E. B., E. Holley-Guthrie, E. C. Mar, M. S. Smith, and S. Kenney. 1990. The Epstein-Barr virus BRLF1 immediate-early gene product transactivates the human immunodeficiency virus type 1 long terminal repeat by a mechanism which is enhancer independent. J. Virol. 64:1817-1820.
53. Quinlivan, E. B., E. A. Holley-Guthrie, M. Norris, D. Gutsch, S. L. Bachenheimer, and S. C. Kenney. 1993. Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter BMRF1. Nucleic Acids Res. 21:1999-2007.
54. Raab-Traub, N. 1992. Epstein-Barr virus and nasopharyngeal carcinoma. Semin. Cancer Biol. 3:297-307.
55. Sarnow, P., Y. S. Ho, J. Williams, and A. Levine. 1982. Adenovirus E1B-58 kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54kd cellular protein. Cell 28:387-394.
56. Shen, W.-J., H. S. Kim, and S. Y. Tsai. 1995. Stimulation of human insulin receptor gene expression by retinoblastoma gene product. J. Biol. Chem. 270:20525-20529.
57. Sinclair, A. J., M. Brimmell, F. Shanahan, and P. J. Farrell. 1991. Pathways of activation of the Epstein-Barr virus productive cycle. J. Virol. 65:2237-2244.
58. Sommer, M. H., A. L. Scully, and D. H. Spector. 1994. Transactivation by the human cytomegalovirus IE2 86-kilodalton protein requires a domain that binds to both the TATA box-binding protein and the retinoblastoma protein. J. Virol. 68:6223-6231.
59. Stellar, H. 1995. Mechanisms and genes of cellular suicide. Science 267: 1445-1449.
60. Sterner, J. M., Y. Murata, H. G. Kim, S. B. Kennett, D. J. Templeton, and J. M. Horowitz. 1995. Characterization of cellular proteins that form complexes with the amino-terminus of the retinoblastoma (Rb) protein: a novel cell-cycle regulated kinase associates with Rb in G2/M phases. J. Biol. Chem. 270:9281-9288.
61. Sterner, J. M., Y. Tao, S. B. Kennett, H. G. Kim, and J. M. Horowitz. 1996. The amino terminus of the retinoblastoma (Rb) protein associates with a cyclin-dependent kinase-like kinase via Rb amino acids required for growth suppression. Cell Growth Differ. 7:53-64.
62. Stinski, M. F. 1977. Synthesis of proteins and glycoproteins in cells infected with human cytomegalovirus. J. Virol. 23:751-767.
63. St. Jeor, S. C., T. B. Albrecht, F. D. Funk, and F. Rapp. 1974. Stimulation of cellular DNA synthesis by human cytomegalovirus. J. Virol. 13:353-362.
64. Szekely, L., K. Pokrovskaja, W.-Q. Jiang, G. Selivanova, M. Lowbeer, N. Ringertz, K. G. Wiman, and G. Klein. 1995. Resting B-cells, EBV-infected B-blasts and established lymphoblastoid cell lines differ in their RB, p53 and EBNA-5 expression patterns. Oncogene 13:1413-1421.
65. Szekely, L., G. Selivanova, K. P. Magnusson, G. Klein, and K. G. Wiman. 1993. EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc. Natl. Acad. Sci. USA 90:5455-5459.
66. Takada, K. 1984. Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt's lymphoma lines. Int. J. Cancer 33:27-32.
67. Takada, K., K. Horinouchi, Y. Ono. T. Aya, M. Osato, M. Takahashi, and S. Hayasaka. 1991. An Epstein-Barr virus-producer line Akata: establishment of the cell line and analysis of viral DNA. Virus Genes 5:147-156.
68. Takada, K., and Y. Ono. 1989. Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J. Virol. 63:445-449.
69. Takada, K., N. Shimuzu, S. Sakuma, and A. Keating. 1986 Transactivation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV BamHI Z DNA fragment. J. Virol. 57:1016-1022.
70. Tanaka, S., T. Furukawa, and S. A. Plotkin. 1975. Human cytomegalovirus stimulates host cell RNA synthesis. J. Virol. 15:297-304.
71. Taya, Y. 1997. RB kinases and RB-binding proteins: new points of view. Trends Biochem. Sci. 22:14-17.
72. Udvadia, A. J., K. T. Rogers, P. D. R. Higgins, Y. Murata, K. H. Martin, P. A. Humphrey, and J. M. Horowitz. 1993. Sp-1 binds promoter elements regulated by the RB protein and Sp-1-mediated transcription is stimulated by RB coexpression. Proc. Natl. Acad. Sci. USA 90:3265-3269.
73. Udvadia, A. J., D. J. Templeton, and J. M. Horowitz. 1995. Functional interactions between the retinoblastoma (Rb) protein and Sp-family members: superactivation by Rb requires amino acids necessary for growth suppression. Proc. Natl. Acad. Sci. USA 92:3953-3957.
74. Vousden, K. H. 1993. Interaction of human papillomavirus transforming proteins with the products of tumor suppressor genes. FASEB J. 7:872-879.
75. Vousden, K. H. 1995. Regulation of the cell cycle by viral oncoproteins. Semin. Cancer Biol. 6:109-116.
76. Wang, J. Y. J., E. S. Knudsen, and P. J. Welch. 1994. The retinoblastoma tumor suppressor protein. Adv. Cancer Res. 64:25-85.
77. Werness, B. A., A. J. Levine, and P. M. Howley. 1990. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76-79.
78. Whyte, P., K. J. Buchkovich, J. M. Horowitz, S. H. Friend, M. Raybuck, R. A. Weinberg, and E. Harlow. 1988. Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature (London) 334:124-129.
79. Wiman, K. G. 1993. The retinoblastoma gene: role in cell cycle control and cell differentiation. FASEB J. 7:841-845.
80. Yew, P. R., and A. J. Berk. 1992. Inhibition of p53 transactivation required for transformation by adenovirus early region 1B protein. Nature (London) 357:82-85.
81. Zalani, S., E. Holley-Guthrie, and S. Kenney. 1996. Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Proc. Natl. Acad. Sci. USA 93:9194-9199.
82. Zalani, S., E. A. Holley-Guthrie, D. E. Gutsch, and S. C. Kenney. 1992. The Epstein-Barr virus immediate-early promoter BRLF1 can be activated by the cellular Sp1 transcription factor. J. Virol. 66:7282-7289.
83. Zhang, Q., D. Gutsch, and S. Kenney. 1994. Functional and physical interaction between p53 and BZLF1: implication for Epstein-Barr virus latency. Mol. Cell. Biol. 14:1929-1938.
84. zur Hausen, H., F. J. O'Neill, U. K. Freese, and E. Hecker. 1978. Persisting oncogenic herpesviruses induced by the tumor promoter TPA. Nature (London) 272:373-375.